TUBERCULOSIS 2003

Cases = 143
Crude Incidence Rate per 100,000 population = 2.3 (U.S., 2002 = 5.2)
Race and Ethnicity-specific Incidence Rates per 100,000 population
  White, not Hispanic or Latino = 1.0
  Black or African-American = 10.8
  Hispanic or Latino, all races = 9.2
  Asian = 29.1
  Hawaiian Native or other Pacific Islander = n/a
  American Indian or Alaska Native = n/a

Gender-specific Incidence Rates per 100,000 population
  Male = 3.1
  Female = 1.6

Tuberculosis (TB) is an airborne disease caused by a group of bacteria that is collectively referred to as the *Mycobacterium tuberculosis* (MTB) complex. The five species in this complex are *M. tuberculosis*, *M. bovis*, *M. africanum*, *M. canettii*, and *M. microti*. General symptoms may include a prolonged, productive cough, blood-tinged sputum, night sweats, fever, fatigue, and weight loss. TB usually affects the lungs, but can also affect other parts of the body like the brain, kidneys, or spine. TB bacteria are aerosolized when a person who has TB of the lungs or larynx coughs, sneezes, laughs, or sings. Another person inhales the droplet nuclei that are formed. Individuals who become infected but do not become ill are considered to have latent TB infection (LTBI) and cannot transmit the infection to others. Approximately 10% of infected individuals will progress to active disease at some point in their lives.

During 2003, 143 new cases of TB were reported to the Indiana State Department of Health. Figures 1a and 1b show long-term and 10-year trends, respectively. The increase from 2002 is due primarily to (1) continued transmission among a group of social contacts in Allen County who were linked to a single case in 2001. This problem was complicated by the patients’ reluctance to name contacts, refusal of some contacts to take preventive therapy, or failure to complete preventive therapy; (2) a two-fold increase in the number of foreign-born cases in Marion County; and (3) an increase in the number of cases among the elderly. TB was reported by 40 of the 92 counties. Five counties accounted for 63% of all cases.

The introduction of anti-TB chemotherapy has led to a long-term decline in the number of deaths as well as the number of new cases. However, deaths still occur from the disease. The number of TB-related deaths is shown in Figure 2. Patients who died after sputum culture conversion to negative, and those who demonstrated significant clinical improvement but died from other causes were excluded.
Figure 1a.

Reported Tuberculosis Cases
1956 - 2003

Figure 1b.

Reported Tuberculosis Cases
10-year Trend, 1994-2003

Figure 2.

Number of TB-Related Deaths
1999-2003
A diagnosis of TB is verified using the Centers for Disease Control and Prevention’s “Case Definitions for Infectious Conditions Under Public Health Surveillance.” TB cases must meet the case definition for either a laboratory or a clinical diagnosis. A laboratory diagnosis is confirmed when *M. tuberculosis* complex has been: (1) isolated from a culture or has been demonstrated in a clinical specimen by a nucleic acid amplification (NAA) test approved by the FDA (must be accompanied by a culture for identification), or (2) acid fast bacilli (AFB) are seen when a culture has not or cannot be obtained (used primarily to aid in a post-mortem diagnosis).

A clinical diagnosis is confirmed when all of the following criteria are met after a completed medical evaluation: (1) a positive tuberculin skin test, (2) signs and symptoms compatible with current TB disease (e.g., an abnormal, unstable chest x-ray) or clinical evidence of current disease (e.g., cough, night sweats, weight loss, hemoptysis), and (2) current treatment with two or more anti-TB drugs. This category includes culture-negative pulmonary TB, extra-pulmonary TB where cultures would not grow or were not obtained, and children in whom obtaining specimens is difficult and invasive procedures are not warranted. Figure 3 shows the percentage of TB cases by case definition.

**Figure 3.**

![TB Classification by Case Definition](image-url)

**TB Classification by Case Definition**

1999-2003

Percent of Cases

<table>
<thead>
<tr>
<th>Year</th>
<th>&quot;+&quot; Lab Test</th>
<th>Clinical Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>81</td>
<td>19</td>
</tr>
<tr>
<td>2000</td>
<td>88</td>
<td>12</td>
</tr>
<tr>
<td>2001</td>
<td>81</td>
<td>19</td>
</tr>
<tr>
<td>2002</td>
<td>91</td>
<td>9</td>
</tr>
<tr>
<td>2003</td>
<td>85</td>
<td>15</td>
</tr>
</tbody>
</table>

ISDH Tuberculosis Control Program
The percentages of new cases by age, sex, race, and ethnicity are as follows:

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage of all new cases:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>66</td>
</tr>
<tr>
<td>Female</td>
<td>34</td>
</tr>
<tr>
<td>White, not Hispanic or Latino</td>
<td>34</td>
</tr>
<tr>
<td>Black or African-American</td>
<td>39</td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>14</td>
</tr>
<tr>
<td>Asian</td>
<td>13</td>
</tr>
</tbody>
</table>

Figure 4 shows case rates per 100,000 population by race, ethnicity, and sex.

**Figure 4.**

**Tuberculosis by Race, Ethnicity, and Sex**

Rate/100,000 for 2003

Foreign-born persons from high-prevalence countries continue to make up a large proportion of TB cases. In 2003, 48 of the 143 TB patients (34%) were born in countries with a high burden of TB (Figure 5). Countries and regions that represent the largest numbers of foreign-born TB cases are shown in Figure 6. Figure 7 shows the length of time they were in U.S. at the time of diagnosis.
The percentages of new cases by age group are as follows:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Percentage of all new cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 15 years</td>
<td>66</td>
</tr>
<tr>
<td>15-24 years</td>
<td>34</td>
</tr>
<tr>
<td>25-44 years</td>
<td>34</td>
</tr>
<tr>
<td>45-64 years</td>
<td>39</td>
</tr>
<tr>
<td>≥ 65 years</td>
<td>14</td>
</tr>
</tbody>
</table>
Case rates by age group are shown in Figure 8.

**Figure 8.**

![Tuberculosis Case Rates by Age Group](image)

The numbers of pediatric cases by age group are shown in Figure 9.

**Figure 9.**

![Pediatric TB Cases](image)

HIV disease is the most significant risk factor for progression to active disease. The percentage of patients according to HIV status is shown in Table 1. The number of cases co-infected with TB and HIV
is shown in Figure 10. HIV counseling and testing recommended for all patients with TB, or suspected of having TB.

Table 1.

HIV Counseling and Testing
Percentage of patients offered counseling and testing

<table>
<thead>
<tr>
<th>Status</th>
<th>Age Group 25-44</th>
<th>All Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tested, results known</td>
<td>68</td>
<td>45</td>
</tr>
<tr>
<td>Patient refused</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Not offered</td>
<td>23</td>
<td>45</td>
</tr>
</tbody>
</table>

Figure 10.

TB and HIV Co-infection
1994-2003

ISDH Tuberculosis Control Program
Other risk factors associated with TB exposure or progression to active disease are excess alcohol use, homelessness, illicit drug use (injecting and non-injecting), and residence in a high-risk congregate setting. The numbers of persons reported with these risk factors at the time of diagnosis are shown in Table 2.

Table 2.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Number of Cases</th>
<th>Percent of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excess alcohol use</td>
<td>32</td>
<td>22</td>
</tr>
<tr>
<td>Injection drug use</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Non-injection drug use</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Homelessness</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Resident of long-term care facility</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Resident of correctional facility</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

2003 (n=143)  *at the time of diagnosis

Occupation is another variable used to detect trends. These data are shown in Table 3. The “not employed” category includes retired persons, children, and students. The health-care workers with TB were all born in countries with high rates of TB and have been in the U.S. for fewer than five years.

Table 3.

<table>
<thead>
<tr>
<th>Occupation</th>
<th>Number of Cases</th>
<th>Percent of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Employed In Last 2 Years</td>
<td>89</td>
<td>62</td>
</tr>
<tr>
<td>Other occupations</td>
<td>51</td>
<td>36</td>
</tr>
<tr>
<td>Migrant agricultural worker</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Health care worker</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Correctional facility employee</td>
<td>0</td>
<td>N/A</td>
</tr>
</tbody>
</table>

2003 (n=143)  *at the time of diagnosis
The number of TB cases classified by the site of disease is shown in Figure 11.

**Figure 11.**

![Pie chart showing TB cases by site of disease, 2003](image)

Source: Indiana State Department of Health TB Control Program

The Indiana State Department of Health recommends and supports the treatment guidelines set by the American Thoracic Society and the Centers for Disease Control and Prevention. Since 1991, these guidelines have recommended that four drugs be used in the initial treatment phase. Unless contraindicated, all patients should begin therapy on the preferred regimen containing isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA), and ethambutol (EMB). The percentage of patients who were started on the standard four-drug regimen is shown in Figure 12.
Drug susceptibility testing is routinely performed on all culture-positive isolates. On rare occasions, such as specimen contamination, drug susceptibility testing cannot always be performed.

Drug susceptibility testing was performed on all but one isolate in 2003. Of these, 4% (5/118) were resistant to INH, with or without resistance to other first-line drugs, excluding RIF. Multi-drug resistant (MDR) TB is defined as resistance to both INH and RIF. MDR-TB is of particular public health concern since these two drugs are the most effective agents. If the organism is resistant to them, less effective and more expensive second-line drugs must be added, with the treatment period having to be extended from the usual 6-9 months to 18-24 months. There was one case of MDR-TB reported for 2003. The number of drug resistant cases is shown in Figure 13.
Besides drug resistance, inadequate response to therapy and failure to follow the treatment regimen are the major reasons for having to extend the treatment period. Sputum culture conversion data are collected to measure response to therapy. The absence of documentation of culture conversion is most commonly due to inadequate patient follow-up and is addressed with the local health departments. Patients whose sputum cultures have not become negative after two months of treatment may require a longer course of therapy. Those whose symptoms have not improved or are still culture-positive after four months of therapy are classified as treatment failures and should be re-evaluated for drug resistance, as well as failing to adhere to the treatment regimen if they are not on directly observed therapy. The proportion of patients who convert their sputum cultures to negative in two months or less is shown in Figure 14. 2002 is the most recent year with complete data.

Directly observed therapy (DOT) is the most effective way to assure that the patient is complying with the prescribed treatment regimen. DOT is a strategy proven to ensure completion of therapy, with the added benefit of preventing acquired drug resistance. DOT is the best practice and the standard of care in Indiana and should be used for all patients. Every effort must be made to initiate DOT when the patient is first started on therapy. Cohort year 2002 is the most recent period with complete DOT data (Figure 15).
**Figure 14.**

**Sputum Culture Conversion*, 2002**

Elapsed time from start of therapy until the first consistently negative culture

* *sputum culture-positive patients alive at the time of diagnosis who began treatment; excludes those who did not convert but died before completing 2 months of therapy

ISDH Tuberculosis Control Program

**Figure 15.**

**Use of Directly Observed Therapy**

ISDH Tuberculosis Control Program
The first priority of TB elimination efforts is to ensure completion of therapy. Indiana’s goal is to have at least 90% of all patients complete treatment within one year. The completion of therapy index is based on the number of patients for whom treatment for one year or less is indicated. Exclusions from the rate calculations are those who were dead at the time of diagnosis, patients who died before completing therapy, patients who were never started on therapy, and patients with multi-drug resistant disease. Therapy is considered to be incomplete for those patients who were reported as moved, uncooperative or refused, or lost to follow-up.

The current data are for those patients in cohort year 2002. Figure 16 shows the percentage of patients who completed therapy in one year or less, and the total completion rate for all patients.

**Figure 16.**

![Completion of Therapy](image)

The second priority is to identify close contacts to patients with active pulmonary or laryngeal TB, and to encourage treatment for those who are infected. People in this group are at a much higher risk of progressing to active disease than those with latent TB infection (LTBI) who were not close contacts. Contact investigations should be initiated within three working days for sputum smear-positive cases that have a high degree of suspicion for TB. Contact investigations must be performed for all cases of laryngeal and sputum culture-positive pulmonary TB. Persons in the following categories who have LTBI are also at high risk for developing active disease once infected and should be treated regardless of their age: (1) individuals who have been infected within the last two years; (2) injection drug users; (3) persons known or suspected of having HIV infection; (4) persons with certain other medical conditions; (5) persons with a chest x-ray suggestive of previous TB who received inadequate treatment or were not treated; and (6) persons from countries where TB is common.
INH for nine months is the preferred course of treatment for LTBI, regardless of age or HIV status. INH for six months is an acceptable alternative for adults if nine months of treatment is not possible. RIF for four months is an effective alternate regimen. RIF and PZA for two months is no longer recommended for general use due to occurrences of hepatitis requiring hospitalization and several deaths.

The most recent year with final completion of treatment data for infected contacts is for cohort year 2001 and is shown in Figure 17.

**Figure 17.**

![Completion of Treatment for LTBI Infected Contacts](image)

Figure 18 shows the counties that reported 5 or more cases of TB in 2003. The total number for the state is based on persons (1) whose primary residence was in Indiana at the time of diagnosis, and (2) who were verified as having TB disease in a given year. Persons counted in another state and immigrants and refugees who are diagnosed and begin treatment abroad are excluded. Foreign visitors (i.e., students, tourists, etc.) and certain other categories of non-U.S. citizens who are diagnosed in Indiana but who remain in the U.S. for less than 90 days of treatment are also excluded. There were 17 of these “not counted” cases in 2003.

The aggregate number of cases by region is shown in Figure 19. This grouping uses a slightly modified version of the map used to display the state’s bioterrorism preparedness districts.
Figure 18.

Counties with 5 or more verified cases of TB in 2003

State = 143

Case Rate = 2.3/100,000

Drug-resistant TB Cases:

Resistant to INH, w/ or w/o resistance to drugs other than RIF = 5

Resistant to INH and RIF = 1

Resistant to other drugs without resistance to INH or RIF = 5
Aggregate Case Counts Grouped by Multi-County Regions

2003 total = 143